Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

The makers of Wegovy and Zepbound are cutting prices to make the medications more affordable for people without insurance.

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

THE most popular puppy names in Ireland for 2025 have been revealed – with a new favourite topping the list.  Luna, which ...

A recent survey found 42% of people are so fed up with high prices that they are leaving snacks and junk food off their ...

What is obesity? Here's what you need to know about the disease expected to impact 50% of adults worldwide by 2050.